Rapport Therapeutics, Inc. RAPP
At closeNov 9, 2026, 4:30 PM EST
After hours · Nov 9, 4:30 PM ET
- YTD
- -14.07%
- 1 year
- +1.60%
- Market cap
- 1.55B
- Revenue (ttm)
- 20.00M
- EPS (ttm)
- -3.17
- Shares out
- 59.28M
- Forward P/E
- -6.29
- YTD return
- -14.07%
- 1-year return
- +1.60%
- Volume
- 789.00K
- Avg volume
- 745.41K
- Open
- 24.50
- Previous close
- 24.44
- Day's range
- 24.06 – 26.35
- 52-week range
- 22.06 – 52.93
- Beta
- 1.40
- Analysts
- Strong Buy
- Price target
- 64.21 (+146.3%)
- Earnings date
- Mar 9, 2027
5D +0.46 (+1.80%)
Key statistics
- Enterprise value
- 1.06B
- PEG ratio
- 0.00
- Price / sales
- 77.27
- Price / book
- 3.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -75.28M
- Total cash
- 395.03M
- Total debt
- 9.39M
- Return on equity
- -33.33%
- Short % of float
- 10.03%
- 50-day average
- 34.16
- 200-day average
- 35.60
Analyst view
Consensus: strong buy
- Target (low)
- 47.00
- Target (mean)
- 64.21
- Target (high)
- 89.00
- Strong buy1
- Buy15
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 9, 2027
Expected Mar 9, 2027. Consensus EPS estimate -0.81953.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 9, 2027 | Dec 30, 2026 | -0.87 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -1.20 | -0.84 | +0.36 | +30.00% |
| Aug 5, 2026 | Jun 30, 2026 | -0.96311 | -1.19 | -0.23 | -23.56% |
| May 7, 2026 | Mar 31, 2026 | -0.56 | -0.42 | +0.14 | +25.00% |
| Mar 10, 2026 | Dec 31, 2025 | -0.65 | -0.72 | -0.07 | -10.77% |
| Nov 6, 2025 | Sep 30, 2025 | -0.77 | -0.71 | +0.06 | +7.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | UBS | main | Buy | Buy |
| Nov 5, 2026 | Guggenheim | main | Buy | Buy |
| Nov 5, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 21, 2026 | Jones Trading | main | Buy | Buy |
| Oct 21, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 21, 2026 | Guggenheim | main | Buy | Buy |
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- rapportrx.com
News
UBS Maintains Buy on Rapport Therapeutics, Lowers Price Target to $64 - Guggenheim Maintains Buy on Rapport Therapeutics, Lowers Price Target to $66
Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $47 
Rapport Therapeutics Q3 EPS $(0.84) Beats $(1.19) Estimate 
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update 
Rapport Therapeutics to Participate in Upcoming Investor Conferences - Rapport Therapeutics Closes Underwritten Public Offerings Of 9,761,905 Shares At $21.00 Per Share
Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on RAPP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BREDT DAVID | Officer | Conversion of Exercise of derivative security | Feb 18, 2026 | 393,075 |
| CEESAY ABRAHAM N | Chief Executive Officer | Sale | Oct 6, 2026 | 554,703 |
| GAULT CHERYL | Chief Operating Officer | Sale | Sep 29, 2026 | 139,914 |
| HUBER REID M. | Director | Purchase | Sep 11, 2025 | 20,400 |
| IGNELZI TROY A | Chief Financial Officer | Purchase | Oct 20, 2026 | 15,500 |
| MARAGANORE JOHN M | Director | Purchase | Oct 21, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.10% | 7,172,894 | 187.00M | Jun 29, 2026 |
| Trv Gp V, LLC | 10.59% | 6,280,525 | 163.73M | Jun 29, 2026 |
| Arch Venture Management, Llc | 6.29% | 3,728,738 | 97.21M | Jun 29, 2026 |
| Capital International Investors | 4.93% | 2,921,958 | 76.18M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.91% | 2,910,449 | 75.88M | Jun 29, 2026 |
| Blackrock Inc. | 4.55% | 2,699,786 | 70.38M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 5.26% | 3,121,012 | 81.36M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.92% | 2,324,788 | 60.61M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.66% | 986,730 | 25.72M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.34% | 793,826 | 20.70M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.19% | 702,995 | 18.33M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.02% | 603,306 | 15.73M | Sep 29, 2026 |